Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegteograstim for chemotherapy-induced neutropenia in pediatric solid tumors
NCT02787876Phase 2Unknown
- Sponsor
- Samsung Medical Center
- Start
- Oct 2016
- Primary completion
- Oct 2018
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 2, open-label trial of pegteograstim in chemotherapy-induced neutropenia (CIN), sponsored by Samsung Medical Center. Primary endpoint: Rate of adverse events at 3 weeks. Status: unknown.
02
Drugs
pegteograstim
03
Conditions
chemotherapy-induced neutropenia (CIN)
Beyond the preview
Go deeper on NCT02787876.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02787876.